Data-derived Extrapolation Factors at 3 Different Ages in Human Males for Bifenthrin, Cyphenothrin, Cyfluthrin, and Cyhalothrin in Brain and Plasma
| Dose . | Age . | Bifenthrin . | Cyphenothrin . | Cyfluthrin . | Cyhalothrin . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Plasma Cmax . | Brain Cmax . | Plasma Cmax . | Brain Cmax . | Plasma Cmax . | Brain Cmax . | Plasma Cmax . | Brain Cmax . | |||
| HED | 5 vs 25 | 1.04 | 1.02 | 0.80 | 0.69 | 0.91 | 0.77 | 0.92 | 0.76 | |
| +10-fold HED | 1.03 | 0.95 | 0.80 | 0.71 | 0.96 | 0.80 | 0.99 | 0.77 | ||
| −10-fold HED | 1.07 | 1.01 | 0.76 | 0.65 | 0.93 | 0.80 | 0.92 | 0.79 | ||
| POD | 1 vs 25 | 1.11 | 1.16 | 0.80 | 0.66 | 0.98 | 0.75 | 0.97 | 0.77 | |
| +10-fold HED | 1.12 | 1.13 | 0.84 | 0.68 | 1.01 | 0.78 | 1.04 | 0.81 | ||
| −10-fold HED | 1.09 | 1.13 | 0.79 | 0.67 | 1.03 | 0.77 | 0.95 | 0.74 | ||
| HED | 0.5 vs 25 | 1.12 | 1.24 | 0.77 | 0.60 | 0.98 | 0.73 | 0.99 | 0.77 | |
| +10-fold HED | 1.11 | 1.15 | 0.82 | 0.67 | 1.04 | 0.77 | 1.03 | 0.77 | ||
| −10-fold HED | 1.14 | 1.20 | 0.78 | 0.62 | 1.03 | 0.77 | 0.95 | 0.74 | ||
| Dose . | Age . | Bifenthrin . | Cyphenothrin . | Cyfluthrin . | Cyhalothrin . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Plasma Cmax . | Brain Cmax . | Plasma Cmax . | Brain Cmax . | Plasma Cmax . | Brain Cmax . | Plasma Cmax . | Brain Cmax . | |||
| HED | 5 vs 25 | 1.04 | 1.02 | 0.80 | 0.69 | 0.91 | 0.77 | 0.92 | 0.76 | |
| +10-fold HED | 1.03 | 0.95 | 0.80 | 0.71 | 0.96 | 0.80 | 0.99 | 0.77 | ||
| −10-fold HED | 1.07 | 1.01 | 0.76 | 0.65 | 0.93 | 0.80 | 0.92 | 0.79 | ||
| POD | 1 vs 25 | 1.11 | 1.16 | 0.80 | 0.66 | 0.98 | 0.75 | 0.97 | 0.77 | |
| +10-fold HED | 1.12 | 1.13 | 0.84 | 0.68 | 1.01 | 0.78 | 1.04 | 0.81 | ||
| −10-fold HED | 1.09 | 1.13 | 0.79 | 0.67 | 1.03 | 0.77 | 0.95 | 0.74 | ||
| HED | 0.5 vs 25 | 1.12 | 1.24 | 0.77 | 0.60 | 0.98 | 0.73 | 0.99 | 0.77 | |
| +10-fold HED | 1.11 | 1.15 | 0.82 | 0.67 | 1.04 | 0.77 | 1.03 | 0.77 | ||
| −10-fold HED | 1.14 | 1.20 | 0.78 | 0.62 | 1.03 | 0.77 | 0.95 | 0.74 | ||
The main value in the table is the results of the equation: Juvenile Cmax_50th percentile/Adult Cmax_50th percentile.
Human Equivalent Dose (HED) 0.89, 2.13, 0.7706, and 0.44 mg/kg/day for bifenthrin, cyphenothrin, cyfluthrin, and cyhalothrin, respectively; +10-fold HED indicates the use of a 10-fold higher dose than the HED; −10-fold HED indicates the use of a 10-fold lower dose than the HED.
Abbreviation: POD, point of departure.
Data-derived Extrapolation Factors at 3 Different Ages in Human Males for Bifenthrin, Cyphenothrin, Cyfluthrin, and Cyhalothrin in Brain and Plasma
| Dose . | Age . | Bifenthrin . | Cyphenothrin . | Cyfluthrin . | Cyhalothrin . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Plasma Cmax . | Brain Cmax . | Plasma Cmax . | Brain Cmax . | Plasma Cmax . | Brain Cmax . | Plasma Cmax . | Brain Cmax . | |||
| HED | 5 vs 25 | 1.04 | 1.02 | 0.80 | 0.69 | 0.91 | 0.77 | 0.92 | 0.76 | |
| +10-fold HED | 1.03 | 0.95 | 0.80 | 0.71 | 0.96 | 0.80 | 0.99 | 0.77 | ||
| −10-fold HED | 1.07 | 1.01 | 0.76 | 0.65 | 0.93 | 0.80 | 0.92 | 0.79 | ||
| POD | 1 vs 25 | 1.11 | 1.16 | 0.80 | 0.66 | 0.98 | 0.75 | 0.97 | 0.77 | |
| +10-fold HED | 1.12 | 1.13 | 0.84 | 0.68 | 1.01 | 0.78 | 1.04 | 0.81 | ||
| −10-fold HED | 1.09 | 1.13 | 0.79 | 0.67 | 1.03 | 0.77 | 0.95 | 0.74 | ||
| HED | 0.5 vs 25 | 1.12 | 1.24 | 0.77 | 0.60 | 0.98 | 0.73 | 0.99 | 0.77 | |
| +10-fold HED | 1.11 | 1.15 | 0.82 | 0.67 | 1.04 | 0.77 | 1.03 | 0.77 | ||
| −10-fold HED | 1.14 | 1.20 | 0.78 | 0.62 | 1.03 | 0.77 | 0.95 | 0.74 | ||
| Dose . | Age . | Bifenthrin . | Cyphenothrin . | Cyfluthrin . | Cyhalothrin . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Plasma Cmax . | Brain Cmax . | Plasma Cmax . | Brain Cmax . | Plasma Cmax . | Brain Cmax . | Plasma Cmax . | Brain Cmax . | |||
| HED | 5 vs 25 | 1.04 | 1.02 | 0.80 | 0.69 | 0.91 | 0.77 | 0.92 | 0.76 | |
| +10-fold HED | 1.03 | 0.95 | 0.80 | 0.71 | 0.96 | 0.80 | 0.99 | 0.77 | ||
| −10-fold HED | 1.07 | 1.01 | 0.76 | 0.65 | 0.93 | 0.80 | 0.92 | 0.79 | ||
| POD | 1 vs 25 | 1.11 | 1.16 | 0.80 | 0.66 | 0.98 | 0.75 | 0.97 | 0.77 | |
| +10-fold HED | 1.12 | 1.13 | 0.84 | 0.68 | 1.01 | 0.78 | 1.04 | 0.81 | ||
| −10-fold HED | 1.09 | 1.13 | 0.79 | 0.67 | 1.03 | 0.77 | 0.95 | 0.74 | ||
| HED | 0.5 vs 25 | 1.12 | 1.24 | 0.77 | 0.60 | 0.98 | 0.73 | 0.99 | 0.77 | |
| +10-fold HED | 1.11 | 1.15 | 0.82 | 0.67 | 1.04 | 0.77 | 1.03 | 0.77 | ||
| −10-fold HED | 1.14 | 1.20 | 0.78 | 0.62 | 1.03 | 0.77 | 0.95 | 0.74 | ||
The main value in the table is the results of the equation: Juvenile Cmax_50th percentile/Adult Cmax_50th percentile.
Human Equivalent Dose (HED) 0.89, 2.13, 0.7706, and 0.44 mg/kg/day for bifenthrin, cyphenothrin, cyfluthrin, and cyhalothrin, respectively; +10-fold HED indicates the use of a 10-fold higher dose than the HED; −10-fold HED indicates the use of a 10-fold lower dose than the HED.
Abbreviation: POD, point of departure.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
